IDH1 is an inclusion eligibility criterion in 4 clinical trials for WHO grade II glioma, of which 4 are open and 0 are closed. Of the trials that contain IDH1 status and WHO grade II glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 3 clinical trials for WHO grade II glioma, of which 3 are open and 0 are closed. Of the trials that contain IDH2 status and WHO grade II glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [3].

PDGFA is an inclusion eligibility criterion in 1 clinical trial for WHO grade II glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFA status and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFB is an inclusion eligibility criterion in 1 clinical trial for WHO grade II glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFB status and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for WHO grade II glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for WHO grade II glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) [3].